Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (311-320 of 713) with videos related to

Pageof 72
Sort By:
Blood|August 4, 2007
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemiaEhab Atallah, Jorge Cortes, Susan O'Brien, et al.
International Journal of Hematology|September 20, 2020
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemiaJorge Cortes, Nikolai Podoltsev, Hagop Kantarjian, et al.
Leukemia Research|July 23, 2014
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemiaNaval Daver, Aditi Shastri, Tapan Kadia, et al.
Leukemia & Lymphoma|February 28, 2007
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phaseAlfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Leukemia Research|July 15, 2016
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosisDai Chihara, Lucia Masarova, Kate J Newberry, et al.
Cancer|April 25, 2003
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemiaSrdan Verstovsek, Taghi Manshouri, Franklin O Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2005
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylateJean-Pierre J Issa, Vazganush Gharibyan, Jorge Cortes, et al.
Leukemia Research|September 15, 2014
Clinical significance of microcytosis in patients with primary myelofibrosisPaolo Strati, Naveen Pemmaraju, Zeev Estrov, et al.
Cancer|June 22, 2010
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunctionWei-Gang Tong, Hagop Kantarjian, Susan O'Brien, et al.
Current Hematologic Malignancy Reports|December 31, 2010
Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?Deborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
Pageof 72

Showing results (311-320 of 713) with videos related to

Sort By:
Pageof 72
Blood|August 4, 2007
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemiaEhab Atallah, Jorge Cortes, Susan O'Brien, et al.
International Journal of Hematology|September 20, 2020
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemiaJorge Cortes, Nikolai Podoltsev, Hagop Kantarjian, et al.
Leukemia Research|July 23, 2014
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemiaNaval Daver, Aditi Shastri, Tapan Kadia, et al.
Leukemia & Lymphoma|February 28, 2007
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phaseAlfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Leukemia Research|July 15, 2016
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosisDai Chihara, Lucia Masarova, Kate J Newberry, et al.
Cancer|April 25, 2003
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemiaSrdan Verstovsek, Taghi Manshouri, Franklin O Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2005
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylateJean-Pierre J Issa, Vazganush Gharibyan, Jorge Cortes, et al.
Leukemia Research|September 15, 2014
Clinical significance of microcytosis in patients with primary myelofibrosisPaolo Strati, Naveen Pemmaraju, Zeev Estrov, et al.
Cancer|June 22, 2010
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunctionWei-Gang Tong, Hagop Kantarjian, Susan O'Brien, et al.
Current Hematologic Malignancy Reports|December 31, 2010
Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?Deborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
Pageof 72